Keratoconus and Corneal Crosslinking (CCL) Treatment
Keratoconus occurs when the transparent layer located at the front of the eye known as the cornea, in conjunction with progressive myopia and astigmatism, thins and tapers into a more conical shape. The patient is not comfortable with glasses or contact lenses, and does not have full vision. The most common complaint is that glasses need to be change frequently and after a short time these new glasses do not provide adequate vision. The disease usually begins in adolescence, progresses between the ages of 20 to 40, then enters a period of recession after the age of 40. In the most advanced form of the disease, when vision is seriously effected, corneal transplant may be required. If you have a family history of this condition you are at a higher risk. Early diagnosis is very important.
Use of UV Cross Linking (CCL) Treatment to stop the eye disease Keratoconus:
The goal here is to strengthen the structure of the cornea, and stop the disease. To do this, riboflavin eye drops and ultraviolet-A light is used. As a result of the interaction of riboflavin and UV-A, free radicals build up on the cornea and causes new bonds to form across adjacent cornea fibres. The cornea becomes stronger and progression of the disease is stopped. This procedure has no toxic side effects on any other ocular tissues, the effect is limited entirely to the cornea. The eye does not need to be covered after the procedure, only protective soft contact lenses are used for a few days and then removed